David J. Wambeke Net Worth

The estimated Net Worth of David J. Wambeke is at least $2.31 millió dollars as of 16 November 2023. David Wambeke owns over 20,000 units of DiaMedica Therapeutics stock worth over $2,308,759 and over the last 2 years David sold DMAC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Wambeke DMAC stock SEC Form 4 insiders trading

David has made over 3 trades of the DiaMedica Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently David bought 20,000 units of DMAC stock worth $49,200 on 16 November 2023.

The largest trade David's ever made was buying 468,750 units of DiaMedica Therapeutics stock on 10 April 2023 worth over $750,000. On average, David trades about 131,779 units every 55 days since 2023. As of 16 November 2023 David still owns at least 527,114 units of DiaMedica Therapeutics stock.

You can see the complete history of David Wambeke stock trades at the bottom of the page.

What's David Wambeke's mailing address?

David's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.

Insiders trading at DiaMedica Therapeutics

Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg és David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.

What does DiaMedica Therapeutics do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Complete history of David Wambeke stock trades at DiaMedica Therapeutics

DiaMedica Therapeutics executives and stock owners

DiaMedica Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich John Pauls MBA,
  Pres, CEO & Director
• Rick Pauls,
  President, Chief Executive Officer, Director
• Dr. Harry W. Alcorn Jr., Pharm.D.,
  Sr. VP of Clinical Operations
• Scott B. Kellen C.A.,
  CFO & Company Sec.
• James Parsons,
  Director
• Michael Giuffre,
  Independent Director
• Jerry Xiao,
  Director
• Harry Alcorn,
  Director
• Paul Papi,
  Vice President - Business Development
• Sydney Gilman,
  Vice President - Regulatory Affairs
• Scott Kellen,
  Chief Financial Officer, Corporate Secretary
• Richard Pilnik,
  Independent Chairman of the Board
• Dr. Edward G. Calamai Ph.D.,
  Consulting Head of Manufacturing
• Tanya Lewis,
  Director
• David J. Wambeke,
  Chief Business Officer
• Jantrill Ab Stahlberg,
  
• Dietrich John Pauls,
  President and CEO
• Zhenyu Xiao,
  Director
• Todd A. Verdoorn,
  Chief Scientific Officer
• Koch Thomas Tom Enterprise ...,
  
• Koch Thomas Tom Enterprise ...,
  
• Charles Pauling Semba,
  Director
• Amy L. Burroughs,
  Director
• Kirsten L Gruis,
  Chief Medical Officer
• Dominic R Cundari,
  Chief Commercial Officer
• Julie Van Orsdel Daves,
  SVP Clinical Development Oper.
• Masuoka K. Lorianne,
  Chief Medical Officer
• Richard Kuntz,
  Director